Inventor

FELDMANN MARC

GB21 patents

⚠️ This page may combine multiple inventors who share the name “FELDMANN MARC”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

FELDMANN MARC

KENNEDY RHEUMATOLOGY INST

Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexate

TNFα receptor-derived binding protein

Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexate

Use of cannabinoids as anti-inflammatory agents

Nucleic acid encoding modified human tnfα (tumor necrosis factor alpha) receptor

Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate

Method of identifying a compound that selectively inhibits cytokine-stimulated T cell induced production of TNF-alpha by monocytes

Small molecular weight TNF receptor multimeric molecule

Activation and inhibition of the immune system

Methods for enhancing antigen presentation

KENNEDY INST OF RHEUMATOLOGY

Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies

Method for treating multiple sclerosis

TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis

Methods of preventing or treating thrombosis with tumor necrosis factor antagonists

180 THERAPEUTICS LP

Method of treating early stage Dupuytren&#39;s disease

Method of treating dupuytren&#39;s disease using a pre-filled syringe

Method of treating a localized fibrotic disorder using an IL-33 antagonist

THE KENNEDY TRUST FOR RHEUMATOLOGY RES

Methods for reducing post-operative cognitive dysfunction (POCD)

Methods for reducing post-operative cognitive dysfunction (POCD)

FELDMANN MARC

Concomitant treatment of rheumatoid arthritis with anti-TNF-α antibodies and methotrexate

LARSEN GLENN

Method of treating a localized fibrotic disorder using an IL-33 antagonist

Method of treating early stage Dupuytren's disease

Method of treating dupuytren's disease using a pre-filled syringe